Navigation Links
Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
Date:3/13/2008

SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that it has initiated a Phase 2 study of RAV12, its lead clinical product, in combination with gemcitabine in the treatment of patients with metastatic pancreatic cancer.

The Phase 2 Pancreatic Cancer Study will be conducted at approximately 20 institutions in the US. The first institution to open the trial is the Fox Chase Cancer Center in Philadelphia, PA. Eight sites will participate through the clinical trials consortium, the Pancreatic Cancer Research Team. More information regarding the study can be found at http://www.clinicaltrials.gov.

After an initial dose-escalation run-in segment of approximately 18 patients, the Phase 2 trial will enroll 63 patients in an efficacy segment. The target dose and schedule of RAV12, 0.75 mg/kg twice weekly, was chosen in a recently completed Phase 1/2a trial that involved 53 patients. Final analysis of the Phase 1/2a study will be available the third quarter of 2008.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, and colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly cytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibod
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
2. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
3. Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
4. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
7. Inclinix Announces New Patent for Expert System Platform
8. Genzyme Announces Presentation of New Positive Data on Carticel(R)
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 New-generation electronic designs ... portable and lightweight. Simultaneously, circuitry is increasing the ... speed to which it performs at. Connecting cables ... and military equipment, such as cameras or detectors, ... and nano-circular connectors include custom cable designs for ...
(Date:6/18/2013)... Australia And EMERYVILLE, Calif. ... Pharmaceuticals, Inc. presented final results today from a ... extended release) capsules demonstrating a statistically significant improvement ... from baseline at week 8 versus placebo in ... Adamas, investigational extended-release formulation of amantadine intended for ...
(Date:6/18/2013)... --  Polymer Technology Systems, Inc. (PTS) announced ... to integrate the CardioChek ® PA system ... systems across the country. The CardioChek PA lipid ... Hanson Medical Systems , offers immediate, on-site ... triglycerides, and glucose. (Logo: http://photos.prnewswire.com/prnh/20130618/DE33611LOGO ...
Breaking Medicine Technology:Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3
... , , , , ... Group (MRG), the global authority on medical technology market intelligence, ... Chinese drug-eluting stent market in 2009, and will continue to ... Asia Pacific Markets for Interventional Cardiology Devices 2010 report ...
... CHARLOTTESVILLE, Virginia, December 16 ... Top Innovator Presentation Award,in Healthcare, at the 2009 New ... The award, which recognizes cutting edge private companies,driving the ... with,over 50 other privately held companies that play a ...
Cached Medicine Technology:Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3Biovista Inc. Named Top Innovator in Life Sciences 2
(Date:6/18/2013)... using technology developed at Case Western Reserve University,s ... of Engineering, has made available avatarsvirtual patientsto train ... and others training to evaluate speech-language disorders to ... on the trainee, because a diagnosis doesn,t have ... , Graduate students studying to become speech-language pathologists ...
(Date:6/18/2013)... The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) ... President’s Emergency Plan for AIDS Relief (PEPFAR) to mark ... in the global effort to eliminate pediatric HIV/AIDs. ... of June 2013, one million babies globally have been ... inception in 2003, EGPAF has been a key implementer ...
(Date:6/18/2013)... 2013 A new $119 million industry ... aquaculture industry is redefining the way consumers get their ... acclaimed personal culinary chefs on the Emerald Coast panhandle ... sustainable seafood and the promising industry of aquaculture. , ... Many consumers strive to fully partake in the effort, ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 New York magazine ... to its “Best Doctors” list, up from 129 last ... City. The new issue also lists 52 additional doctors who ... on a strategic growth trajectory. The “Best Doctors” issue, which ... the June 24 print issue and is available online at ...
(Date:6/18/2013)... to keep their scheduled medical appointments and their ... listens, explains things clearly and knows them as a ... suggests. , "If people feel their doctor really knows ... has their best interests at heart and may be ... Tabor E. Flickinger, M.D., M.P.H., a fellow in the ...
Breaking Medicine News(10 mins):Health News:SimuCase avatars advance speech-language pathology training 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3Health News:New $119 Million Industry Swimming Up the East Coast 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3Health News:Respect may be the key to stopping patient 'no shows' 2
... their new studies that the analysis of the placenta could ... from the University of Yale stated that they believe to ... by analysing and seeking out certain biological abnormalities present in ... disorder that affects a child's social learning and communication skills, ...
... for normal immune functioning found to be safe when ... - a new study finds. ,Visceral leishmaniasis, ... donovani, affects certain internal organs. People in tropical and ... this infectious disease through the bite of a sand ...
... 400 adult volunteers revealed compounds, which stimulate growth hormone ... ,The results of a study published at the ... of growth hormone work in adults to improve their ... ,The results will be presented by Dr. George ...
... new studies published in the Mayo Clinic Proceedings revealed ... use with the onset of cardiac syndromes.// ,‘Broken ... of breath mimics heart attack. ,The ... somewhat uncommon disorder first described in Japan 15 years ...
... giant Cipla has received the approval from the Food and ... anti-HIV/AIDS// drug Slamivudine," according to a posting on the FDA ... for ANDA is for an oral solution with strength of ... of drugs called as nucleoside reverse transcriptase inhibitors. It stops ...
... achievement, scientists at the Central Drug Research Institute (CDRI) here ... - a growing problem afflicting many across the country. ... that the existing anti-depression drugs. It is also free of ... told IANS. ,Elaborating on the drug, he said, ...
Cached Medicine News:Health News:Analysis of Placenta Helps In Diagnosis of Autism At Birth 2Health News:Lack of STAT1 -an Immune Protein, Pack Liver Infection Cure 2Health News:Lack of STAT1 -an Immune Protein, Pack Liver Infection Cure 3Health News:Growth Hormone Stimulants help to Combat Aging Symptoms 2Health News:Growth Hormone Stimulants help to Combat Aging Symptoms 3Health News:Sudden Opioid Withdrawal Results in ‘Broken Heart Syndrome 2
Sphincter of Oddi Solid State Catheter Adapter Cable for Polygraf ID...
... diagnosis of influenza A and ... due to the availability of ... of influenza using Clearview Exact ... lead to reduced hospital stays, ...
... A1c-Cellular is the first HbA1c control available ... the entire HbA1c procedure including the lysing ... is a ready-to-use liquid control with an ... closed-vial stability of six months when refrigerated. ...
...
Medicine Products: